Alcohol Dependence Clinical Trial
Official title:
Real-time fMRI Neurofeedback as a Treatment Tool for Alcohol Dependence
NCT number | NCT02486900 |
Other study ID # | BRAINTRAINAD |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2015 |
Est. completion date | August 2018 |
Verified date | January 2019 |
Source | Cardiff University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to examine whether the neurofeedback method (based on functional magnetic resonance imaging [fMRI]) can help patients with alcohol dependence to control their urges to drink alcohol and thus to remain abstinent. Potential effects of neurofeedback on abstinence and drinking behaviour will be evaluated based on the comparison between a group of patients receiving multiple sessions of neurofeedback training and a group of patients receiving treatment as usual over the same period of time.
Status | Completed |
Enrollment | 52 |
Est. completion date | August 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Successful completion of detoxification programme within a time window of 1 to 6 months before the recruitment - Abstinence since detoxification treatment Exclusion Criteria: - Ongoing regular abuse of illicit substances except cannabis - History of psychotic disorders not related to alcohol - IQ < 70 - Involvement in other interventional research in the past 6 months - MRI counter-indications, e.g. claustrophobia, pregnancy, active medical implants, passive implants deemed unsuitable, metallic dust in the eyes, certain types of metal prostheses, surgical clips, previous experience with metalworking without eye protection |
Country | Name | City | State |
---|---|---|---|
United Kingdom | School of Medicine, Cardiff University | Cardiff | Wales |
Lead Sponsor | Collaborator |
---|---|
Cardiff University | European Commission |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Indices of drinking (continuous) - % days abstinent | Derived from the Timeline Followback Calendar. | 4 months after baseline assessment/first training | |
Primary | Indices of drinking (continuous) - drinks per drinking day | Derived from the Timeline Followback Calendar. | 4 months after baseline assessment/first training | |
Primary | Indices of drinking (continuous) - % days of 'heavy drinking' | Defined as 8 or more alcohol units per day/men or 6 or more units/women. Derived from the Timeline Followback Calendar. | 4 months after baseline assessment/first training | |
Secondary | Drinking urges/craving assessed with the Drinking Urges Questionnaire (DUQ) | Assessed 4 months, 8 months and 12 months after baseline | ||
Secondary | Drinking urges/craving assessed with the Obsessive Compulsive Drinking Scale (OCDS) | Assessed 4 months, 8 months and 12 months after baseline | ||
Secondary | Drinking urges/craving (attentional bias) assessed with the alcohol stroop test | Assessed 4 months, 8 months and 12 months after baseline | ||
Secondary | Craving self-ratings during scanning (neurofeedback group only) | Assessed 2, 4, 6, 8, 12, 16 weeks after baseline (each training session) | ||
Secondary | Profile of Mood States Questionnaire | Assessed 4 months, 8 months and 12 months after baseline | ||
Secondary | Beck Depression Inventory | Assessed 4 months, 8 months and 12 months after baseline | ||
Secondary | Hospital Anxiety and Depression Scale | Assessed 4 months, 8 months and 12 months after baseline | ||
Secondary | NHS Resource Use Questionnaire | Assessed 4 months, 8 months and 12 months after baseline | ||
Secondary | Debriefing Questionnaire (neurofeedback group only) | Assessed 2, 4, 6, 8, 12, 16 weeks after baseline (each training session) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 | |
Completed |
NCT00226694 -
Alcohol and Gender Effects on Stress Circuit Function
|
N/A |